Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
AbbVie announced the acquisition of DJS Antibodies, a UK-based biotechnology firm, for $255 million. DJS specializes in developing antibody therapies targeting difficult proteins, with its leading candidate DJS-002 aimed at treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. This deal enhances AbbVie's antibody research capabilities and solidifies its immunology portfolio, leveraging DJS's proprietary HEPTAD platform. AbbVie anticipates retaining DJS employees and its Oxford facility, with additional payments contingent on DJS-002's development milestones.
On October 17, 2022, AbbVie announced the retirement of Laura J. Schumacher, vice chairman and chief legal officer, after a notable 32-year career. Perry C. Siatis was appointed as the new executive vice president, general counsel, and secretary. Schumacher played a pivotal role in AbbVie’s formation and led significant legal functions, including the $63 billion acquisition of Allergan. Siatis, with over 17 years at AbbVie, has managed various legal responsibilities and contributed to the company’s growth and compliance programs.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), showcased its commitment to aesthetic medicine at the American Society for Dermatologic Surgery (ASDS) meeting from October 6-10, 2022, in Denver. Key findings include a low global rate (<0.016%) of delayed-onset nodules from dermal fillers on the Vycross platform, based on 15 years of data. The event featured eight scientific abstracts, including studies on facial hyperpigmentation and innovative treatment solutions. Dr. DiAnne Davis presented the Forces of Beauty® Report, addressing racial equity in aesthetic medicine.
AbbVie (NYSE: ABBV) is set to announce its third-quarter 2022 financial results on October 28, 2022, before market opening. A live webcast of the earnings call will occur at 8 a.m. CT, accessible through AbbVie's Investor Relations website. An archived version will be available later the same day. AbbVie aims to deliver innovative medicines across various therapeutic areas, addressing serious health issues, including immunology, oncology, and more. For further details, visit the company's official website.
AbbVie (NYSE: ABBV) presented new data from studies on risankizumab (SKYRIZI) and upadacitinib (RINVOQ) during the United European Gastroenterology (UEG) Week 2022. Key highlights include final analyses from the U-ACHIEVE study, which evaluated RINVOQ's efficacy in treating moderately to severely active ulcerative colitis, and the U-EXCEL study focusing on Crohn's disease. A total of 17 abstracts, featuring oral presentations and e-posters, showcase AbbVie's commitment to advancing treatments for inflammatory bowel disease. The investigational use of these medications in Crohn's disease in the EU is noted.
AbbVie’s Allergan Aesthetics and skinbetter science launched the Forces of Beauty report on Sept. 22, 2022, under the DREAM Initiative. The report explores racial representation in beauty standards, revealing that only 17% of women feel their racial beauty is accepted. Key findings show 1 in 4 women of color perceive beauty standards as racist. In tandem, a new royalty-free image gallery, resulting from a partnership with Shutterstock Studios, aims to promote diverse representations across various demographics. The initiative seeks to foster dialogue and education around inclusive beauty.
AbbVie (NYSE: ABBV) received a positive opinion from the EMA's CHMP for risankizumab (SKYRIZI®) to treat adults with moderately to severely active Crohn's disease. The recommendation stems from three Phase 3 studies showing significant improvements in clinical remission and endoscopic response at 12 weeks post-treatment. If approved, this would be the first specific IL-23 inhibitor available for Crohn's disease in the EU. A final European Commission decision is expected in Q4 2022, marking the third indication for risankizumab in the region.
AbbVie announced it will present findings from the Phase 3 M15-736 trial and data on BOTOX at the 2022 MDS International Congress in Madrid from September 15-18. Key presentations include results on the continuous infusion of ABBV-951 for advanced Parkinson's disease and real-world efficacy of BOTOX for spasticity and cervical dystonia. AbbVie emphasizes its commitment to addressing the needs of patients with movement disorders, reinforcing its leadership in neuroscience.
AbbVie has opened public voting for its 30th annual Cystic Fibrosis (CF) Scholarship program, running until September 28. This year, 40 students living with CF are competing for two $25,000 scholarships based on academic excellence and community involvement. Earlier in 2022, AbbVie awarded $3,000 to 40 CF students, totaling over $3.7 million in scholarships since the program's inception. The winners will be announced in early November, highlighting AbbVie's commitment to supporting the CF community.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced the selection of 25 real patients for its new BOTOX® Cosmetic 'See Yourself' campaign after receiving nearly 20,000 submissions. The campaign aims to showcase authentic testimonials and experiences, reflecting the emotional and physical impact of BOTOX® treatments. The latest content includes interviews, treatment diaries, and informative sessions addressing common patient inquiries. BOTOX® Cosmetic remains the leading product in its category, approved by the FDA for treating facial lines.
